Zacks Small Cap Weighs in on Lantern Pharma Q2 Earnings

Lantern Pharma Inc. (NASDAQ:LTRN) – Research analysts at Zacks Small Cap issued their Q2 2025 earnings estimates for shares of Lantern Pharma in a note issued to investors on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will earn ($0.53) per share for the quarter. The consensus estimate for Lantern Pharma’s current full-year earnings is ($1.90) per share. Zacks Small Cap also issued estimates for Lantern Pharma’s Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.43) EPS and FY2027 earnings at ($1.62) EPS.

Separately, Lake Street Capital started coverage on shares of Lantern Pharma in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $25.00 target price on the stock.

Lantern Pharma Stock Down 3.1%

Shares of NASDAQ LTRN opened at $3.48 on Wednesday. Lantern Pharma has a 12 month low of $2.55 and a 12 month high of $6.80. The company has a market cap of $37.53 million, a price-to-earnings ratio of -1.96 and a beta of 1.63. The business has a fifty day simple moving average of $3.53 and a 200-day simple moving average of $3.74.

Lantern Pharma (NASDAQ:LTRN) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.07. During the same quarter in the prior year, the firm earned ($0.51) earnings per share.

Institutional Trading of Lantern Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Perigon Wealth Management LLC increased its holdings in Lantern Pharma by 169.8% in the first quarter. Perigon Wealth Management LLC now owns 39,387 shares of the company’s stock worth $139,000 after buying an additional 24,787 shares during the last quarter. Voss Capital LP acquired a new stake in Lantern Pharma in the fourth quarter valued at approximately $160,000. Renaissance Technologies LLC increased its stake in shares of Lantern Pharma by 3.9% during the 4th quarter. Renaissance Technologies LLC now owns 87,300 shares of the company’s stock worth $278,000 after purchasing an additional 3,300 shares during the last quarter. BIOS Capital Management LP bought a new position in shares of Lantern Pharma during the 4th quarter valued at $3,853,000. Finally, CM Management LLC raised its holdings in shares of Lantern Pharma by 8.1% during the 4th quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $638,000 after purchasing an additional 15,000 shares in the last quarter. 28.62% of the stock is currently owned by hedge funds and other institutional investors.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.